Health Catalyst insider files Form 144 to sell 15,726 shares

Health Catalyst, Inc. reported a Form 144 notice for the proposed sale of 15,726 shares of common stock to be sold through Morgan Stanley Smith Barney LLC on 03/02/2026.

Rhea-AI Filing Summary

Health Catalyst, Inc. reported a Form 144 notice for the proposed sale of 15,726 shares of common stock to be sold through Morgan Stanley Smith Barney LLC on 03/02/2026.

The filing also discloses recent insider sales by Kevin Freeman: 16,401 shares sold on 12/01/2025 for $47,566.18 and 6,614 shares sold on 02/26/2026 for $11,559.95.

Insights

Corporate Governance Analyst

Form 144 shows a planned brokered sale and recent insider dispositions by Kevin Freeman.

The filing lists a proposed sale of 15,726 shares through Morgan Stanley Smith Barney LLC on 03/02/2026. This is presented as a notice of intent to sell under the securities rules; timing and execution depend on broker and regulatory conditions.

Past transactions recorded include sales of 16,401 shares on 12/01/2025 for $47,566.18 and 6,614 shares on 02/26/2026 for $11,559.95. Subsequent filings will show executed sales and final proceeds.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Health Catalyst's Form 144 disclose about proposed sales?

It discloses a proposed sale of 15,726 shares to be executed through Morgan Stanley Smith Barney on 03/02/2026. The notice indicates the intention to sell common stock under the securities rules; execution details depend on broker and clearance.

Who is the insider named and what recent sales are reported for HCAT?

Kevin Freeman is named as the reporting person with recent sales of 16,401 shares on 12/01/2025 for $47,566.18 and 6,614 shares on 02/26/2026 for $11,559.95. These are reported as past transactions.

Through which broker will the proposed HCAT sale occur?

The proposed sale is to be handled by Morgan Stanley Smith Barney LLC, listed with an address at 1 New York Plaza, 38th Floor, New York, NY. The filing names the broker as the intermediary for the proposed transaction on 03/02/2026.

Are the proceeds from the proposed 15,726-share sale disclosed in the Form 144?

The excerpt does not state proceeds for the 15,726-share proposed sale. The filing lists the share quantity and broker for 03/02/2026; proceeds or prices for that proposed sale are not provided in the provided excerpt.

Do the recent insider sales appear in the filing as executed transactions?

Yes, two executed sales by Kevin Freeman are reported: 16,401 shares on 12/01/2025 for $47,566.18 and 6,614 shares on 02/26/2026 for $11,559.95. These are listed under securities sold during the past three months.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 07:14 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001945797
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Health Catalyst, Inc.
SEC File Number	001-38993
Address of Issuer	10897 S River Front Pkwy #300 South Jordan UTAH 84095
Phone	8553096800
Name of Person for Whose Account the Securities are To Be Sold	Kevin Freeman
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Other

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th Floor New York NY 10004	15726	26103.59	70730884	03/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/02/2026	Restricted Stock	Health Catalyst, Inc.			15726	03/02/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Kevin Freeman c/o 10897 South River From Parkway #100 South Jordan UT 84095	Restricted Stock	12/01/2025	16401	47566.18
Kevin Freeman c/o 10897 South River From Parkway #100 South Jordan UT 84095	Restricted Stock	02/26/2026	6614	11559.95

144: Remarks and Signature

Remarks
Date of Notice	03/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Kevin Freeman
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)